Literature DB >> 28680008

Spontaneous regression of chemotherapy-resistant metastases from a scalp angiosarcoma.

Masahiro Suzuki1, Takashi Matsuzuka1, Masakazu Ikeda1, Yuta Nakaegawa1, Tetsuro Kobayashi1, Tomotaka Kawase1, Takehiro Kobari1, Shigeyuki Murono1.   

Abstract

Angiosarcomas are rare malignant tumors derived from endothelial cells and occur most commonly in the scalp and the face. The prognosis is poor. Therefore, spontaneous regression of angiosarcoma is a rare phenomenon.We describe a case of a 73-year-old man with multiple metastatic angiosarcoma.In the present case, weekly paclitaxel therapy had an effect, but could not be continued because of interstitial pneumonia (IP). Weekly docetaxel therapy did not have an effect, but further chemotherapy was not carried out because aggravation of the IP was a concern.The primary lesion and other metastatic lesions were inconspicuous on the positron emission tomography/computed tomography scan performed in one year and two months after best supportive care.We reported an extremely rare case of spontaneous regression of therapy-resistant metastases of angiosarcoma that has remained controlled for 40 months since the initial diagnosis.

Entities:  

Keywords:  Angiosarcoma; Chemotherapy; Metastases; Spontaneous Regression; malignant tumor

Mesh:

Year:  2017        PMID: 28680008      PMCID: PMC5597530          DOI: 10.5387/fms.2016-20

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  15 in total

1.  Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

Authors:  Isabelle Ray-Coquard; Antoine Italiano; Emmanuelle Bompas; Axel Le Cesne; Yves-Marie Robin; Christine Chevreau; Jacques-Olivier Bay; Guilhem Bousquet; Sophie Piperno-Neumann; Nicolas Isambert; Laurent Lemaitre; Charles Fournier; Eric Gauthier; Olivier Collard; Didier Cupissol; Stéphanie Clisant; Jean-Yves Blay; Nicolas Penel
Journal:  Oncologist       Date:  2012-01-27

2.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Authors:  Nicolas Penel; Binh Nguyen Bui; Jacques-Olivier Bay; Didier Cupissol; Isabelle Ray-Coquard; Sophie Piperno-Neumann; Pierre Kerbrat; Charles Fournier; Sophie Taieb; Marta Jimenez; Nicolas Isambert; Frédéric Peyrade; Christine Chevreau; Emmanuelle Bompas; Etienne G C Brain; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 3.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

4.  Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome.

Authors:  N Penel; A Italiano; I Ray-Coquard; L Chaigneau; C Delcambre; Y M Robin; B Bui; F Bertucci; N Isambert; D Cupissol; E Bompas; J O Bay; F Duffaud; C Guillemet; J Y Blay
Journal:  Ann Oncol       Date:  2011-05-12       Impact factor: 32.976

5.  Angiosarcomas of the head and neck: clinical and pathologic characteristics.

Authors:  M R Aust; K D Olsen; J E Lewis; A G Nascimento; N B Meland; R L Foote; V J Suman
Journal:  Ann Otol Rhinol Laryngol       Date:  1997-11       Impact factor: 1.547

6.  Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.

Authors:  S Stacchiotti; E Palassini; R Sanfilippo; B Vincenzi; M G Arena; A M Bochicchio; P De Rosa; A Nuzzo; S Turano; C Morosi; A P Dei Tos; S Pilotti; P G Casali
Journal:  Ann Oncol       Date:  2011-04-04       Impact factor: 32.976

7.  Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells.

Authors:  J Xiang; Z Chen; H Huang; T Moyana
Journal:  Leuk Res       Date:  2001-10       Impact factor: 3.156

8.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

Authors:  M Agulnik; J L Yarber; S H Okuno; M von Mehren; B D Jovanovic; B E Brockstein; A M Evens; R S Benjamin
Journal:  Ann Oncol       Date:  2012-08-21       Impact factor: 32.976

9.  Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.

Authors:  Timothy M Pawlik; Augusto F Paulino; Cornelius J McGinn; Laurence H Baker; Deborah S Cohen; Jeffery S Morris; Riley Rees; Vernon K Sondak
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

Review 10.  Angiosarcoma. A report of 67 patients and a review of the literature.

Authors:  R J Mark; J C Poen; L M Tran; Y S Fu; G F Juillard
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

View more
  2 in total

1.  Spontaneous Regression of Myxofibrosarcoma of the Thigh after Open Biopsy.

Authors:  Tsukasa Mizuno; Michiro Susa; Keisuke Horiuchi; Hideyuki Shimazaki; Kuniaki Nakanishi; Kazuhiro Chiba
Journal:  Case Rep Oncol       Date:  2019-05-16

Review 2.  [Angiosarcoma of the shoulder revealed by previous trauma: about a case and literature review].

Authors:  Manix Ilunga Banza; Israël Badypwyla Tshiamala; Augustin Kibonge Mukakala; Christelle Ngoie Ngoie; Néron Tapenge Shutsha; Stéphane Ilunga Mukangala; Vincent De Paul Kaoma Cabala; Mireille Meuke Tchankui; Trésor Kibangula Kasanga; Nathalie Dinganga Kapessa
Journal:  Pan Afr Med J       Date:  2020-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.